<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Woods EJ</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><pagination>300</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7405448</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Deceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be recovered in 3-5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; (b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate</pubmed_abstract><journal>Journal of translational medicine</journal><pubmed_title>Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.</pubmed_title><pmcid>PMC7405448</pmcid><funding_grant_id>1R43AI129444-01A1</funding_grant_id><pubmed_authors>Sherry AM</pubmed_authors><pubmed_authors>Woods EJ</pubmed_authors><pubmed_authors>Brandacher G</pubmed_authors><pubmed_authors>Woods JR</pubmed_authors><pubmed_authors>Hardin JW</pubmed_authors><pubmed_authors>LaFontaine M</pubmed_authors><pubmed_authors>Johnstone BH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.</name><description>&lt;h4>Background&lt;/h4>Deceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be recovered in 3-5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; (b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Aug</publication><modification>2026-05-03T20:38:53.662Z</modification><creation>2020-08-15T07:03:25Z</creation></dates><accession>S-EPMC7405448</accession><cross_references><pubmed>32758261</pubmed><doi>10.1186/s12967-020-02470-1</doi></cross_references></HashMap>